FloQast Raises $100 Million In Series E Funding Round Led By ICONIQ Growth

RAISE IMAGE: Andy Cohen, Mike Whitmire & Roy Luo DATE: 04/11/2024 COMPANY: FloQast INVESTORS: WiL (World Innovation Lab), Sapphire Ventures, Meritech Capital Partners, ICONIQ Growth & BDT & MSD Partners ROUND: Series E AMOUNT: $100,000,000 VALUATION: $1,600,000,000 NOTE: FloQast, a leading provider of finance and accounting operations platforms, has raised US$100 million in a Series E funding round led by ICONIQ Growth, propelling the company to a post-money valuation of US$1.6 billion. With participation from BDT & MSD Partners and World Innovation Lab (WiL) and continued support from Meritech Capital and Sapphire Ventures, this funding signifies a significant milestone in FloQast's journey. CEO and Co-Founder Mike Whitmire highlighted the company's commitment to empowering finance and accounting teams worldwide with innovative AI-driven solutions, aiming to enhance efficiency, accuracy, and compliance. With a client base including industry giants like Twilio and Zoom, FloQast is poised to continue its trajectory of growth, innovation, and global expansion. HQ: #ShermanOaks #California #VentureCapital #FloQast #WiL #WorldInnovationLab #SapphireVentures #MeritechCapitalPartners #ICONIQGrowth #BDTandMSDPartners #MikeWhitmire #RoyLuo #AndyCohen #TradedVC

More Deals

View All

Eli Lilly Acquires AtaiBeckley For Up To $3.8 Billion In Psychedelic Medicine DealEli Lilly is making its biggest move yet into psychedelic medicine through its planned acquisition of AtaiBeckley in a deal valued at up to $3.8 billion, the largest acquisition in the sector to date. The transaction centers on AtaiBeckley’s lead program, BPL-003, an intranasal 5-MeO-DMT therapy for treatment-resistant depression that is advancing into Phase 3 trials, along with a second DMT-based candidate in development. Founder Christian Angermayer said the focus is now on getting these therapies “into the hands of millions of patients around the globe as quickly as possible.” The deal reflects growing investor and pharmaceutical interest in psychedelic-based mental health treatments, following recent acquisitions by AbbVie and Otsuka as clinical evidence and policy support continue to strengthen across the field. SALE PRICE: $3,800,000,000 #VentureCapital #EliLilly #AtaiBeckley #TradedVC

Tempus AI Acquires Personalis In $1.5 Billion All-Stock TransactionTempus AI announced a definitive agreement to acquire Personalis in an all-stock transaction valued at approximately $1.5 billion in enterprise value, bringing together two longtime partners in cancer monitoring and precision oncology. The acquisition builds on a collaboration that began in 2023 and expanded through Tempus’ strategic investment and exclusive commercialization partnership for Personalis’ NeXT Personal MRD test, which detects molecular residual disease and helps monitor cancer recurrence. Under the agreement, Personalis shareholders will receive $16.25 per share, representing a 6% premium to the company’s recent closing price. Personalis CEO Chris Hall said the deal offers the greatest value to shareholders and accelerates access to the company’s cancer testing technologies. The transaction is expected to close in late 2026 or early 2027, subject to shareholder and regulatory approvals. SALE PRICE: $1,500,000,000 HQ: Chicago, Illinois #VentureCapital #TempusAI #Personalis #TradedVC

Neo Secures $100 Million Funding Led By Andreessen Horowitz And Bessemer Venture PartnersNeo, a Boston-based cybersecurity startup focused on securing AI agents and agentic software, has emerged from stealth with $100 million in total funding, including a $75 million Series A led by Andreessen Horowitz and Bessemer Venture Partners, alongside participation from Craft Ventures and Merlin Ventures, following a previously undisclosed $25 million seed round. Founded by Nick Warner, Shlomi Salem, and Eran Shirazi, Neo provides SecOps teams with real-time inventory, risk intelligence, attribution, and policy controls to govern AI agents operating across enterprise environments. The company plans to use the funding to expand its engineering and go-to-market teams as demand grows for tools that help organizations manage the security risks posed by increasingly autonomous AI systems. FOUNDERS: Nick Warner, Shlomi Salem & Eran Shirazi INVESTORS: Andreessen Horowitz, Bessemer Venture Partners, Craft Ventures & Merlin Ventures ROUND: Seed + Series A AMOUNT: $100,000,000 HQ: Boston, Massachusetts #VentureCapital #Neo #TradedPartner #AndreessenHorowitz #TradedVC

Brookfield Asset Management And CPP Investments Acquire LXP Industrial Trust For $5.2 BillionBrookfield Asset Management and Canada Pension Plan Investment Board (CPP Investments) have agreed to acquire LXP Industrial Trust in an all-cash transaction valued at approximately $5.2 billion, including net debt and preferred equity, taking the industrial REIT private upon closing. Under the deal, LXP shareholders will receive $61.20 per share in cash, representing significant premiums to the company’s recent trading averages. LXP owns a portfolio of roughly 53 million square feet of warehouse and logistics properties across key U.S. Sunbelt and Midwest markets. LXP Chairman and CEO Thomas W. Eglin, Jr. described the transaction as the culmination of the company’s transformation into a pure-play industrial REIT, while Brookfield Real Estate CEO Lowell Baron said the acquisition aligns with Brookfield’s strategy of investing in high-quality real estate with durable cash flows and value-creation opportunities through active asset management. The transaction is expected to close in the fourth quarter of 2026, subject to shareholder approval and customary conditions. SALE PRICE: $5,200,000,000 #VentureCapital #BrookfieldAssetManagement #CanadaPensionPlanInvestmentBoard #LXPIndustrialTrust #TradedVC